Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
all-trans retinoid acid
DRUG
2 trials
Sponsors
University of Ulm
, Technische Universität Dresden
Conditions
Acute Myeloid Leukemia
Leukemia, Promyelocytic, Acute
Phase 3
Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result
Completed
NCT00146120
University of Ulm
Acute Myeloid Leukemia
Start: 1998-05-31
End: 2005-05-31
Target: 400
Updated: 2009-02-09
Phase 4
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
NCT00180128
Technische Universität Dresden
Leukemia, Promyelocytic, Acute
Start: 2000-01-31
End: 2012-11-30
Target: 80
Updated: 2011-07-11
Related Papers
Clinical implications of subclonal <i>TP53</i> mutations in acute myeloid leukemia
Haematologica
2018-10-11
93 citations
Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG)
Blood
2016-12-02
10 citations
Genomic Classification and Prognosis in Acute Myeloid Leukemia
New England Journal of Medicine
2016-06-08
4221 citations
Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG)
Blood
2015-12-03
5 citations
Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG)
Blood
2015-12-03
1 citations
Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG)
Blood
2013-11-15
1 citations
Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome
Blood
2013-11-15
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.
2009-07-14
218 citations